Fellow Ottawa-area firms ImaSight Corp. and Liponex Inc. finalize their $10-million merger. Gatineau-based digital X-ray solutions maker ImaSight reports it has wrapped up its previously announced amalgamation deal with Ottawa’s Liponex Inc., currently developing a drug to increase “good cholesterol,” which has been shown to reduce the risk of heart disease. “We are pleased to acquire the assets of Liponex,” says ImaSight CEO John Brooks. “I believe there is value in the patent portfolio of Liponex and we plan to realize on that value for the benefit of the shareholders.” Liponex CEO Bill Dickie is reportedly leaving the combined company, while Liponex founder and chief scientific officer Dr. Dan Sparks, along with his team, will stay on.